Next Article in Journal
Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment
Next Article in Special Issue
Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer
Previous Article in Journal
The Protein Phosphatase PPM1G Destabilizes HIF-1α Expression
Previous Article in Special Issue
Inflammatory Markers and MicroRNAs: The Backstage Actors Influencing Prognosis in Colorectal Cancer Patients
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(8), 2298; https://doi.org/10.3390/ijms19082298

The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

1
Department of Oncology, University Hospital of Pisa, 56126 Pisa, Italy
2
Department of Translational Research and New Technologies in Medicine, University of Pisa, 56126 Pisa, Italy
3
Department of Oncology, Azienda Sanitaria Universitaria Integrata S. Maria della Misericordia, 33100 Udine, Italy
*
Author to whom correspondence should be addressed.
Received: 27 June 2018 / Revised: 31 July 2018 / Accepted: 1 August 2018 / Published: 5 August 2018
(This article belongs to the Special Issue Basic and Translational Research in Colorectal Cancer)
Full-Text   |   PDF [600 KB, uploaded 7 August 2018]   |  

Abstract

In the evolving molecular landscape of metastatic colorectal cancer, optimizing available tools to select patients to receive anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies is a modern challenge of colorectal oncologists. Several molecular biomarkers have been investigated in recent years as potential predictors of resistance to anti-EGFR agents in preclinical and clinical retrospective series. Nevertheless, none of them have been implemented in clinical practice due to the lack of a formal prospective demonstration. Here, we propose a literature review of molecular alterations associated with resistance to anti-EGFRs, underlining the reasons why their roadmap from laboratories to clinics was prematurely halted. View Full-Text
Keywords: metastatic colorectal cancer; biomarkers; anti-EGFR agents; primary resistance; negative selection metastatic colorectal cancer; biomarkers; anti-EGFR agents; primary resistance; negative selection
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Antoniotti, C.; Ongaro, E.; Falcone, A.; Cremolini, C. The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. Int. J. Mol. Sci. 2018, 19, 2298.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top